Research in contextEvidence before this studyStaging fibrosis is crucial for the prognosis and to determine the rapid need of treatment in patients with schistosomiasis. Circulating miRNAs have been proposed as having potential as predictors of fibrotic disease progression. However, limited information is available in terms of using circulating miRNAs to trace the progression of hepatic fibrosis in schistosomiasis. We searched PubMed for studies published in English before Oct 1, 2017 reporting the use of circulating miRNAs as biomarkers in fibrosis grading. We used "fibrosis" and "circulating" or "diagnostic" and "miRNA" or "biomarker" as search terms. Five studies of direct relevance were identified. Ten miRNAs were selected to test for potential in grading schistosomiasis liver fibrosis based on their correlation with virus-related hepatic fibrosis and/or myocardial fibrosis progression.Added value of this studyOf the validated circulating miRNAs, four (miR-150-5p, let-7a-5p, let-7d-5p and miR-146a-5p) were able to distinguish patients with mild versus severe fibrosis due to schistosomiasis, with the level of serum miR-150-5p showing the most promise for grading schistosome-induced hepatic fibrosis. The diagnostic performance of miR-150-5p in discriminating mild from severe fibrosis is comparable with that of the ELF test and serum HA level.Implications of all the available evidenceThe current study suggests that circulating miRNAs can be a supplementary tool for assessing hepatic fibrosis in human schistosomiasis; however, detection of the four circulating miRNAs here provided only moderate diagnostic value for staging schistosomal hepatic fibrosis. Thus, further steps, such as identifying more potential miRNAs specific for schistosomiasis fibrosis by profiling, increasing human sample numbers, and/or testing serum/plasma vesicle-derived miRNAs, may be required to determine whether an improvement on the ability of circulating miRNAs in grading schistosomiasis liver fibrosis can be achieved.Alt-text: Unlabelled Box

1. Introduction {#s0020}
===============

Schistosomiasis, a major neglected tropical disease of poverty, affects \>230 million people worldwide \[[@bb0055]\]. Three species of schistosomes (trematode blood flukes), *Schistosoma mansoni*, *S. haematobium* and *S. japonicum,* are the most clinically relevant The annual number of disability-adjusted life years (DALYs) lost for this disease has been estimated to be up to 3.5 million in 2015 \[[@bb0165]\]. Currently, the control of the disease predominantly relies on mass drug administration (MDA) programs with praziquantel (PZQ).

Chronic infection with *S. japonicum* or *S. mansoni*, known as hepatosplenic schistosomiasis, exhibits clinical pathology features comprising granuloma formation, periportal fibrosis, portal hypertension, hepatosplenomegaly, ascites, and the formation of vascular shunts \[[@bb0035]\]. The hepatic pathology during hepatosplenic schistosomiasis is trigged by soluble egg antigen (SEA) secreted from mature eggs lodged in host liver tissue. Immune cells recruited to the periphery of eggs create a type 2 cytokine (interleukin 4 (IL-4)- and IL-13-)-enriched niche, which leads to the granuloma formation, macrophage differentiation, hepatic stellate cell (HSC) activation and then fibrosis development. The liver residential cells, HSCs, and recruited immune cells (eosinophils, neutrophils, macrophages, and lymphocytes) have been identified as major contributors to these cellular events \[[@bb0050]\].

MicroRNAs (miRNAs) are small non-coding RNAs (18--25 nt), which act as subtle gene expression regulators of a variety of cellular processes, including fibrogenesis \[[@bb0095],[@bb0190]\]. Several studies have shown the dysregulation of miRNAs in liver tissue during schistosome infection in both murine models and human subjects \[[@bb0025],[@bb0035],[@bb0090]\]. MiRNAs can be found in a wide range of body fluids, including plasma and serum \[[@bb0215]\] The high stability of cell-free miRNAs in biofluids has been attributed to the following mechanisms: 1) they are complexed with Argonaute proteins or high-density lipo-proteins \[[@bb0205],[@bb0210]\]; 2) they are incorporated into microvesical/exosomes \[[@bb0010]\]; and 3) their small size and resistance to RNase digestion. As attractive targets for novel diagnosis, circulating miRNAs have been proposed as biomarkers for different diseases and disorders including cancers, and infectious and inflammatory diseases \[[@bb0060],[@bb0125],[@bb0155],[@bb0160]\]. Furthermore, circulating miRNAs have been proposed as having potential as predictors of fibrosis progression \[[@bb0005],[@bb0070],[@bb0130],[@bb0135],[@bb0150]\]. However, as there was limited information available, we aimed to determine the potential of measuring the levels of circulating miRNAs to trace the progression of hepatic fibrosis due to schistosomiasis. Two mouse strains (C57BL/6 and BALB/c) were initially employed to screen ten miRNA candidates by constructing temporal expression profiles in serum during *S. japonicum* infection. Then, six selected candidate miRNAs were validated using human sera from a cohort of individuals resident in a schistosomiasis-endemic area of the rural Philippines. Finally, the serum levels of the six miRNA signatures were assessed in C57BL/6 mice after the regression of schistosome-induced liver fibrosis following treatment with PZQ.

2. Materials and methods {#s0025}
========================

2.1. Ethics statement {#s0030}
---------------------

All work on animal was performed according to the Australian Code for the Care and Use of Animals for Scientific Purposes (8th edition) and with the approval of the QIMR Berghofer Medical Research Institute Animal Ethics Committee (Ethics Approval: Project P288). Human study was approved by the Human Ethics Committee, QIMR Berghofer Medical Research Institute (QIMRB), Brisbane, Australia (Ethics Approval: Project P524) and the Institutional Review Board of the Research Institute for Tropical Medicine, Department of Health, Manila, the Philippines (Institutional Review Board Number 2012-13-0), in accordance with the Declaration of Helsinki. Written informed consent was received from each study participant or from the legal guardians of those aged \<15 years.

2.2. Study cohort {#s0035}
-----------------

The human cohort study was carried out in 18 schistosomiasis-endemic barangays in the municipalities of Laoang and Palapag, Northern Samar, the Philippines. Detailed information of the study population is described elsewhere as part of a hepatic morbidity study \[[@bb0185],[@bb0195]\]. We enrolled 163 individuals (all negative for HBV/HCV infection) from the cohort all of whom were assessed for liver fibrosis severity by ultrasound scan using a portable gray-scale ultrasonogram equipped with 3 MHz curve array transducer (SONOACE X1; Madison Co., Ltd., Seoul, South Korea). Hepatic fibrosis assessment was adopted from the practical standards established for ultrasonography by the WHO/TDR in 2000 (WHO Special Programme for Research and Training in Tropical Diseases). Ultrasound findings were determined by consensus agreement of two experienced ultrasonographers \[[@bb0185]\].

2.3. Mouse infection, serum collection, histological assessment and biochemical analyses {#s0040}
----------------------------------------------------------------------------------------

Eight-week-old female C57BL/6 and BALB/c mice were infected percutaneously with a low challenge dosage (16 ± 2) of *S. japonicum* cercariae. Mice were sacrificed at different time points post infection and \~1 ml blood was collected at each time point by cardiac puncture. The median lobe from each mouse liver was formalin-fixed and subjected to histological assessment \[[@bb0030]\]. Slides were scanned using the Aperio Slide Scanner (Aperio Technologies, Vista, USA). The percent of granuloma volume density (Gra) and of hepatic necrosis (Nec), and the percent of collagen staining (degree of hepatic fibrosis, HF) were quantified using ImageScope V10.2.1 (Aperio) with H&E and picosirius red stained slides, respectively. Liver hydroxyproline (HP) content was measured by a Hydroxyproline Colorimetric Assay Kit (Bioo Scientific, Austin, TX). Serum alanine transaminase (ALT) and aspartate transaminase (AST) levels were determined using ALT and AST color endpoint assay kits (Bioo Scientific, Austin, TX), respectively.

2.4. Mouse infection, drug treatment and sample collection {#s0045}
----------------------------------------------------------

Three groups of eight-week-old female C57BL/6 mice (For each group, *n* = 8) were used in the experiment. One group of uninfected mice was used as control, while other two groups were percutaneously infected with 16 ± 2 *S. japonicum* cercariae. For the latter groups, one group mice were sacrificed at 6 weeks p.i., and blood and liver samples were collected. The other group of mice were orally administered 150, 200, 250, 300 and 350 mg/kg PZQ (Sigma, USA) prepared in 2.5% (*v*/v) Kolliphor EL (Sigma, USA) for 5 consecutive days \[[@bb0040]\], and blood and liver samples were collected, at 6 months post treatment (p.t.). Tubes containing blood were centrifuged at 3000*g* for 10 min at room temperature and the sera retained. Fecal egg burden was assessed at 6 weeks p.i. for both groups of mice \[[@bb0225]\]. The median lobe from each mouse liver was formalin-fixed and subjected to Sirius red staining.

2.5. Serum collection {#s0050}
---------------------

For human serum sampling, \~10 ml blood was collected from each cohort subject enrolled; serum was then obtained by centrifugation, and stored at 2--8 °C. The serum samples were then transferred to a 4 °C cooler box and transported to the Research Institute for Tropical Medicine (RITM), Manila and stored at −80 °C. Subsequently, a subset of samples was transported on dry ice to QIMRB, Australia.

2.6. RNA extraction and qRT-PCR for miRNA quantification {#s0055}
--------------------------------------------------------

Total RNAs were extracted from mouse and human serum samples using the miRNeasy mini kit (Qiagen, Hilden, Germany) with 3.2 fmoles *Arabidopsis thaliana* ath-miR-159a as spike-in control added. Polyadenylation and RT reactions were performed with S-Poly(T) method \[[@bb0030]\]. Quantification of miRNAs was performed by qRT-PCR with the Applied Biosystems ViiA 7 (Applied Biosystems, Foster City, CA) according essentially to protocols described previously \[[@bb0030]\]. Expression levels of miRNAs were normalized to the spike-in ath-miR-159a for analyses. The miRNA expression levels were calculated by the 2~−~^ΔCt^ method (ΔCt was defined as Ct~(miRNA\ of\ interest)~ − Ct~(reference\ gene)~) \[[@bb0150]\].

2.7. Statistical analysis {#s0060}
-------------------------

For analysis of the temporal serum levels of miRNAs in two mouse models during *S. japonicum* infection, one-way ANOVA followed by Holm-Sidak multiple comparison was used. For the assessment of the correlation between continuous variables, Pearson\'s correlation coefficient (r) was used, while for that between continuous and categorical variables, Spearman\'s rank correlation coefficient (rho) was used. The Mann-Whitney *U* test was used for analysis of the ability of the serum levels of miRNAs in discriminating mild (grade 0-I) from severe (grade II-III) hepatic fibrosis in schistosomiasis patients. The receiver operating characteristic (ROC) curve analyses were performed and the area under the curve (AUC) was calculated to assess the feasibility of using the serum levels of miRNAs (or in combination) as potential markers for discriminating mild (grade 0-I) from severe (grade II-III) schistosomiasis hepatic fibrosis. In the PZQ treated schistosomiasis mouse model, the Mann-Whitney *U* test was used for analysis of fecal egg burden and liver collagen deposition between the two infected groups of C57BL/6 mice; a *p*-value of \<0.05 was considered statistically significant. One-way ANOVA followed by Holm-Sidak multiple comparison was used for analysis of the serum levels of miRNAs between control, infected (6 weeks p.i.) and PQZ-treated mice (infected, treated at 6 weeks p.i. and tested at 6 months p.t.). Statistical analysis was performed with GraphPad Prism Version 6.00 for windows.

Further details about the study methods are provided in the Supplementary material.

3. Results {#s0065}
==========

3.1. Temporal expression of serum miRNAs in the two mouse strains during *S. japonicum* infection {#s0070}
-------------------------------------------------------------------------------------------------

Ten miRNAs were selected to test their potential for grading schistosomiasis liver fibrosis based on their correlation with virus-related hepatic fibrosis and/or myocardial fibrosis progression (Supplementary Table 1). Temporal expression of these ten miRNAs was initially investigated in two genetically different murine models of *S. japonicum* infection ([Fig. 1](#f0005){ref-type="fig"}a and b). In C57BL/6 mice, 4 of the 10 miRNAs (miR-200b-3p, let-7d-5p, miR-146a-5p and miR-222) were significantly down-regulated from 4 weeks p.i., except let-7d-5p at 7 weeks p.i., and onwards, while 2 of them (miRNA-150-5p and let-7a-5p) were significantly down-regulated from 6 weeks p.i. and onwards. In BALB/c mice, only miRNA-150-5p presented a similar expression pattern to that found in C57BL/6 mice across the infection course. The serum level of miR-200b-3p was significantly down-regulated at 6 weeks p.i. and onwards. The serum levels of miR-192a-5p and miR-185-5p was significantly increased at 6 weeks p.i. and onwards (except miR-185-5p at 11 weeks p.i.), while the levels of both miRNAs were not altered in C57BL/6 mice during the infection. Furthermore, the level of miR-29a-3p in BALB/c mice was significantly up-regulated at 4 weeks p.i. and onwards, while no statistically significant change in the serum level of miR-29a-3p was observed over the infection course in C57BL/6 mice. The global expression trend of these serum miRNAs in the two mouse strains during *S. japonicum* infection is presented as Supplementary Table 2.Fig. 1Temporal abundance of serum miRNAs in two mouse strains during *S. japonicum* infection. (a) C57BL/6 mice, (week 0, n = 8; week 4, n = 7; week 6, n = 6; week 7, n = 6; week 9, n = 9; week 11, n = 7; week 13, n = 7). (b) BALB/c mice, (week 0, n = 10; week 4, n = 5; week 6, n = 7; week 7, n = 8; week 9, n = 9; week 11, n = 8). Boxes represent the interquartile range of the data. The lines across the boxes indicate the median values. The hash marks above and below the boxes indicate the 90th and 10th percentiles for each group, respectively. *P* values were calculated using One-way ANOVA. (ns = no significant difference, \* = *P* \< 0.05, \*\* = *P* \< 0.01, \*\*\* = *P* \< 0.001, \*\*\*\* = *P* \< 0.0001).Fig. 1

3.2. Correlation of serum miRNA levels with pathological parameters during *S. japonicum* infection in mice {#s0075}
-----------------------------------------------------------------------------------------------------------

We then analyzed the correlations between the serum levels of the ten miRNAs and liver pathological parameters in both C57BL/6 and BALB/c mice ([Table 1](#t0005){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}). The level of miR-192a-5p was most positively correlated with the levels of liver enzymes, followed by miR-29a-3p and miR-185-5p. In contrast, the level of miR-150-5p in serum was most inversely correlated with the levels of liver enzymes. The serum levels of miR-150-5p, miR-200b-3p and miR-146a-5p were inversely correlated with liver HP content, the intensities of hepatic fibrosis and granuloma in both mouse strains (in C57BL/6 mice, for miR-150-5p, r = −0.5770, −0.5435 and −0.5919, and *P* \< 0.0001, \<0.0001 and \< 0.0001, respectively; for miR-200b-3p, r = −0.5249, −0.6013 and −0.6659, and *P* = 0.0002, \<0.0001 and \< 0.0001, respectively; for miR-146a-5p, r = −0.5423, −0.4623 and −0.4807, and *P* \< 0.0001, = 0.0011 and = 0.0006, respectively; in BALB/c mice, for miR-150-5p, r = −0.6530, −0.6010 and −0.6183, and *P* \< 0.0001, \<0.0001 and \< 0.0001, respectively; for miR-200b-3p, r = −0.4461, −0.4206 and −0.4408, and *P* = 0 .0017, 0.0032 and 0.0019, respectively; for miR-146a-5p, r = −0.5529, −0.4414 and −0.4927, and *P* \< 0.0001, = 0.0019 and = 0.0004, respectively). For miR-222, the inverse correlations were only observed in C57BL/6 mice (r = −0.4258, −0.5036 and −0.5396, and *P* = 0.0028, = 0.0003 and \< 0.0001, respectively). In C57BL/6 mice, the levels of miR-let-7a-5p and let-7d-5p in serum were inversely correlated with the intensities of hepatic fibrosis and granuloma (for let-7a-5p, r = −0.3770 and −0.4224, and *P* = 0.0090 and 0.0031, respectively; for let-7d-5p, r = −0.3160 and −0.3427, and *P* = 0.0305 and 0.0184, respectively). The serum level of miR-29a-3p positively correlated with liver HP content, the intensities of hepatic fibrosis and granuloma in BALB/c, but not in C57BL/6 mice. In BALB/c mice, the serum levels of miR-192a-5p and miR-29a-3p were positively correlated with the severity of liver necrosis (r = 0.4517 and 0.5085, and *P* = 0.0014 and 0.0003, respectively).Table 1Correlations of serum miRNA expression levels with pathological parameters in two mouse strains during *S. japonicum* infection.Table 1Mouse strainmiRNAASTALTHPHF[a](#tf0105){ref-type="table-fn"}Gra[a](#tf0105){ref-type="table-fn"}Nec[a](#tf0105){ref-type="table-fn"}*rprprprprprp*C57BL/6miR-92a-3p−0.1647ns−0.1921ns−0.2246ns−0.35500.0144−0.38040.0084−0.1567nsmiR-150-5p−0.30870.0348−0.30100.0398−0.5770\<0.0001−0.5435\<0.0001−0.5919\<0.0001−0.2681nsmiR-192a-5p0.7202\<0.00010.7672\<0.0001−0.0738ns0.0909ns0.0562ns0.0833nsmiR-200b-3p−0.1184ns−0.2637ns−0.52490.0002−0.6013\<0.0001−0.6659\<0.0001−0.32450.0261let-7a-5p−0.1530ns−0.33350.0220−0.1841ns−0.37700.0090−0.42240.0031−0.2200nslet-7d-5p−0.0891ns−0.1959ns−0.2102ns−0.31600.0305−0.34270.01840.0210nsmiR-185-5p0.46470.00100.33170.0227−0.1110ns−0.0618ns−0.0781ns0.1166nsmiR-29a-3p0.49830.00040.41920.00340.2215ns0.2157ns0.2051ns0.0827nsmiR-146a-5p0.2410ns0.1867ns−0.5423\<0.0001−0.46230.0011−0.48070.0006−0.0297nsmiR-2220.0715ns−0.0898ns−0.42580.0028−0.50360.0003−0.5396\<0.0001−0.0475nsBALB/cmiR-92a-3p0.2105ns0.1860ns0.0293ns0.1670ns0.2090ns0.1609nsmiR-150-5p−0.6388\<0.0001−0.6112\<0.0001−0.6530\<0.0001−0.6010\<0.0001−0.6183\<0.0001−0.38730.0072miR-192a-5p0.7241\<0.00010.7586\<0.00010.2508ns0.31410.03150.34390.01790.45170.0014miR-200b-3p−0.39900.0055−0.40410.0049−0.44610.0017−0.42060.0032−0.44080.0019−0.2401nslet-7a-5p0.0045ns−0.0745ns0.2860ns0.28910.04870.2389ns−0.0483nslet-7d-5p−0.1863ns−0.1767ns0.1614ns0.0530ns−0.0072ns−0.0637nsmiR-185-5p0.45730.00120.42490.00290.0807ns0.33140.02290.40050.00530.2711nsmiR-29a-3p0.6135\<0.00010.5729\<0.00010.29610.04330.48630.00050.5596\<0.00010.50850.0003miR-146a-5p−0.34400.0179−0.33950.0196−0.5529\<0.0001−0.44140.0019−0.49270.0004−0.33740.0204miR-222−0.31890.0289−0.33820.0201−0.0076ns0.0410ns−0.0665ns−0.31630.0303[^2][^3][^4]Fig. 2Correlations of expression levels of six miRNAs in serum with the severity of liver fibrosis (sirius red staining) (a) and with the liver hydroxyproline content in *S. japonicum*-infected C57BL/6 and BALB/c mice (Pearson\'s correlation coefficient).Fig. 2

3.3. Correlations of the serum levels of six miRNAs with human schistosomiasis hepatic fibrosis {#s0080}
-----------------------------------------------------------------------------------------------

The expression levels of six miRNAs (miR-192a-5p, let-7a-5p, let-7d-5p, miR-185-5p, miRNA-29a-3p and miR-222) were inconsistent in the two mouse strains during infection with *S. japonicum*. This may have been due in part to the difference in hepatopathology (i.e., a higher level of liver necrosis was induced in BALB/c than in C57BL/6 mice at 6 weeks p.i. \[[@bb0030]\]), which likely fluctuate the levels of serum miRNAs. Therefore, C57BL/6 may represent a better model for exploring for potential circulating miRNA signatures in schistosomiasis liver fibrosis. Thus, six miRNAs (miR-150-5p, miR-200b-3p, let-7a-5p, let-7d-5p, miR-146a-5p and miR-222) dysregulated in C57BL/6 mice during the infection were selected for further validation with clinical samples. The potential association between the serum levels of the six miRNA signatures and fibrosis grades was then investigated in a human cohort from a schistosomiasis-endemic area of the Philippines ([Table 2](#t0010){ref-type="table"}). The levels of four miRNAs (miR-150-5p, let-7a-5p, let-7d-5p and miR-146a-5p) in serum were inversely correlated with hepatic fibrosis grades (*r* = −0.3218, −0.2732, −0.2371 and −0.2756, and *P* \< 0.0001, = 0.0004, = 0.0023 and = 0.0004, respectively) whereas the serum levels of miR-200b-3p and miR-222 did not significantly correlate with hepatic fibrosis grading ([Fig. 3](#f0015){ref-type="fig"}).Table 2*S. japonicum* infection status and intensity of 163 subjects at baseline stratified by fibrosis grade.Table 2Fibrosis grade0 (*n* = 52)I (*n* = 35)II (*n* = 47)III (*n* = 29)M/F23/2924/1137/1028/1Age (years)37.9 ± 16.3134.49 ± 15.8445.51 ± 12.8950.52 ± 12.01  Kato-KatzEPG(0−200)(0--650)(0--633)(0--2750)Negative (0)42212314Mild (1--99)962011Moderate (100--399)1632Heavy (\>400)0212Serological test (+/-)[a](#tf0005){ref-type="table-fn"}25 / 2730 / 544 / 329 / 0[^5][^6]Fig. 3Correlations of expression levels of six miRNAs in human serum with hepatic fibrosis grades (Spearman\'s correlation coefficient).Fig. 3

3.4. Discrimination of hepatic fibrosis grade 0-I and grade II-III by serum levels of six miRNAs {#s0085}
------------------------------------------------------------------------------------------------

The expression levels of miRNA-150-5p, let-7a-5p, let-7d-5p and miRNA-146a-5p in serum were significantly lower in patients with fibrosis grade II-III than in those with grade 0-I (*P* \< 0.0001, = 0.0004, = 0.0027 and = 0.0029, respectively), while the expression levels of miRNA-200-3p and miRNA-222 showed no significant difference between the two groups ([Fig. 4](#f0020){ref-type="fig"}a). The receiver operating characteristic curve analysis for discriminating liver fibrosis grade II-III to 0-I showed that the area under the curve (AUC) levels of miRNA-150-5p, let-7a-5p, let-7d-5p and miRNA-146a-5p were 0.6838, 0.6598, 0.6270 and 0.6575, respectively (*P* \< 0.0001, = 0.0004, = 0.0052 and = 0.0005, respectively) ([Fig. 4](#f0020){ref-type="fig"}b). No significant increase in AUC values was observed for the different combinations of the four circulating miRNAs in discriminating mild (grade 0-I) from severe (grade II-III) schistosomiasis liver fibrosis ([Table 3](#t0015){ref-type="table"}). However, when the two extremes (grade 0 vs grade III) were compared, the AUC levels of miRNA-150-5p, let-7a-5p, let-7d-5p and miRNA-146a-5p were 0.7347, 0.7102, 0.6704 and 0.7172, respectively (*P* = 0.0005, 0.0018, 0.0114 and 0.0013, respectively), which were higher than those obtained in discriminating liver fibrosis grade II-III to 0-I (Supplementary Fig. 1).Fig. 4Discrimination of schistosomiasis mild (grade 0-I) and severe (grade II-III) hepatic fibrosis by expression levels of miRNAs in human serum. (a) Expression levels of the candidate miRNAs in serum of schistosomiasis japonica patients with (grade II-III) or without (grade 0-I) significant liver fibrosis. Boxes represent the interquartile range of the data with lines across the boxes indicate the median values. The hash marks above and below the boxes indicate the 90th and 10th percentiles, respectively. *P* values were determined using a Mann-Whitney *U* test (ns = no significant difference, \*\* = *P* \< 0.01, \*\*\* = *P* \< 0.001, \*\*\*\* = *P* \< 0.0001). (b) ROC curve analysis was performed and the AUCs were calculated to evaluate capabilities of serum miRNA levels for discriminating mild and severe schistosomiasis hepatic fibrosis.Fig. 4Table 3Area under the receiver operating characteristic curve for the different combinations of circulating miRNAs for discriminating mild (grade 0-I) from severe (grade II-III) schistosomiasis liver fibrosis.Table 3miRNA combinationAUC (95% CI)*p*miR-150-5p + let-7a-5p0.6951 (0.6146--0.7756)\<0.0001miR-150-5p + let-7d-5p0.6780 (0.5963--0.7597)\<0.0001miR-150-5p + miR-146a-5p0.6950 (0.6130--0.7771)\<0.0001let-7a-5p + let-7d-5p0.6437 (0.5589--0.7285)0.0016let-7a-5p + miR-146a-5p0.6692 (0.5849--0.7534)0.0002let-7d-5p + miR-146a-5p0.6528 (0.5675--0.7382)0.0008miR-150-5p + let-7a-5p + let-7d-5p0.6764 (0.5944--0.7584)0.0001miR-150-5p + let-7a-5p + miR-146a-5p0.6997 (0.6184--0.7810)\<0.0001miR-150-5p + let-7d-5p + miR-146a-5p0.6834 (0.6012--0.7656)\<0.0001let-7a-5p + let-7d-5p + miR-146a-5p0.6543 (0.5692--0.7394)0.0007miR-150-5p + let-7a-5p + let-7d-5p + miR-146a-5p0.6835 (0.6014--0.7657)\<0.0001

3.5. Analysis of six miRNAs in serum in response to PZQ treatment in C57BL/6 mice post infection {#s0090}
------------------------------------------------------------------------------------------------

C57BL/6 mice were used as a model for exploring the miRNA expression in serum before and after drug treatment. Fecal egg burden was assessed at 6 weeks p.i. in *S. japonicum*-infected C57BL/6 mice (Supplementary Fig. 2), and no significant difference was observed between the un-treated and treated (prior to treatment) groups. Considerable regression of liver fibrosis was observed in PZQ-treated mice at 6 months post-treatment (p.t.) shown by sirius red staining (Supplementary Fig. 3). The serum levels of miRNA-150-5p, miR-200b-3p, let-7a-5p, let-7d-5p, miR-146a-5p and miR-222 were significantly down-regulated at 6 weeks p.i. (*P* \< 0.0001, \< 0.0001, \< 0.0001, = 0.0006, = 0.0275 and = 0.0265, respectively); however, in the PZQ treatment group, the levels of these miRNAs were significantly increased at 6 months p.t. compared with the levels at 6 weeks p.i. (*P* \< 0.0001, \< 0.0001, \< 0.0001, = 0.0002, \< 0.0001 and = 0.0062; respectively) ([Fig. 5](#f0025){ref-type="fig"}).Fig. 5Expression levels of the six candidate miRNAs in the serum of C57BL/6 mice (Control, n = 8; 6 weeks p.i., n = 8; 6 months p.t., n = 8) after infection and PZQ treatment. Boxes represent the interquartile range of the data with lines across the boxes indicating the median values. The hash marks above and below the boxes indicate the 90th and 10th percentiles, respectively. *P* values were determined using a one-way ANOVA test (NS = no significant difference, \* = *P* \< 0.05, \*\* = *P* \< 0.01, \*\*\* = *P* \< 0.001, \*\*\*\* = *P* \< 0.0001).Fig. 5

4. Discussion {#s0095}
=============

The development of hepatopathology in schistosomiasis is a complex process, and mainly includes granuloma formation and the resultant development of liver fibrosis \[[@bb0050]\]. In addition to resident liver cells, immune cells recruited to the periphery of deposited eggs are also involved in the process, concomitant with a complicated regulatory interplay among these cell types. During these events, a complexed dysregulation of gene expression (including miRNAs) occurs in the infected liver tissue \[[@bb0020],[@bb0035]\]. However, recent evidence has shown no direct correlation between the levels of miRNAs in the relevant tissues and in the circulatory system \[[@bb0175]\]. For example, no change of miR-150-5p or miR-200b-3p levels was observed in the liver tissue of BALB/c mice post *S. japonicum* infection \[[@bb0035]\], whereas we show here a down-regulation in the levels of these two miRNA in both infected C57BL/6 and BALB/c mice. This may be due to fact that miRNAs were expressed at different levels within multiple cell populations (resident cells and recruited cells) in the liver, and dysregulation of a specific miRNA usually occurred in particular cell types within the tissue. In addition, it has been argued that miRNA packaging into extracellular vesicles/exosomes is a selective process, although the precise regulatory mechanism for this remains elusive \[[@bb0080],[@bb0115]\].

As one of the five miRNAs highly specific for hematopoietic cells, miR-150 is involved in the progression of renal and cardiac fibrosis \[[@bb0025],[@bb0065],[@bb0105],[@bb0235]\]. Honda et al. \[[@bb0110]\] demonstrated the anti-fibrosis effect of miR-150 in fibroblasts by regulating the expression of integrin β3, phosphorylated Smad3 and COL1A1. Previously, Li et al. \[[@bb0140]\] found that the expression of miR-150 was up-regulated in the serum of HBV patients compared with controls although no association with the severity of fibrosis was assessed in this study. Recently, Lambrecht et al. \[[@bb0130]\] showed that circulating vesicle-associated miR-150, but no plasma miR-150 showed potential as a biomarker for early stage HBV- and HCV-induced liver fibrosis. Here, we present evidence that miR-150-5p shows promise in discriminating mild hepatic fibrosis from the severe form in schistosomiasis. The level of miRNA-150-5p showed a weak reverse correlation with the scores of ELF test and the values of the direct liver fibrosis marker HA in serum (Supplementary Table 3), which strengthen the association between this miRNA with the progression of schistosome-induced hepatic fibrosis.

The biological function of the let-7 family member, let-7b, has been revealed in the murine model of schistosomiasis, and has been shown to act as a negative regulator of hepatic fibrosis via the down-regulation of TβRI \[[@bb0200]\]. Recently, Matsuura et al. \[[@bb0150]\] showed that the levels of circulating let-7 family members in plasma declined significantly over time during the progression of fibrosis in chronic hepatitis C, with an AUC value of 0.776, 0.734 and 0.790 for let-7a-5p, let-7c-5p and let-7d-5p, respectively. Similar to these observations, we show that let-7a-5p (AUC: 0.6598) and let-7d-5p (AUC: 0.6270) circulating in serum can discriminate between mild and severe schistosomiasis hepatic fibrosis, indicating that these let-7 family members may represent etiology-independent signatures for liver fibrosis.

The regulatory roles of miR-146a-5p in various types of fibrosis have been recently documented \[[@bb0075],[@bb0100],[@bb0120],[@bb0170],[@bb0240]\]. During *S. japonicum* infection, it was shown that miR-146 is considerably up-regulated in liver macrophages, suppressing the IFN-γ-induced differentiation of macrophages to M1 cells through targeting STAT1 \[[@bb0100]\]. Differential expression of miR-146a in serum has also been observed in patients with advanced fibrosis and cirrhosis (F3-F4) and mild and moderate fibrosis (F1-F2) with chronic hepatitis C (CHC), but not with chronic hepatitis B (CHB) \[[@bb0005]\]. The CHC patients with F3-F4 had higher levels of miR-146a in their sera compared with those with F1-F2. In contrast, we found this miRNA was down regulated in the sera of C57BL/6 mice over the course of *S. japonicum* infection. Furthermore, lower levels of this miRNA were detected in the sera of human subjects with severe (II-III) hepatic fibrosis compared with those with mild (0-I) disease. These observations support our suggestion that the serum expression of some miRNA signatures may be etiology-dependent during the development of fibrosis.

Recent studies have shown that miR-200b plays a role in the development of fibrosis in a variety of tissues, including cardiac fibroblast fibrosis, precancerous oral submucous fibrosis, early pulmonary fibrosis, interstitial fibrosis, and liver fibrosis \[[@bb0045],[@bb0145],[@bb0220],[@bb0230]\]. Moreover, it has been documented that miR-222 promotes the progression of liver fibrosis through regulating the activation of HSCs \[[@bb0180]\]. Although the serum levels of miR-200b-3p and miR-222 were significantly down-regulated in C57BL/6 mice during the course of *S. japonicum* infection, both miRNAs failed to discriminate mild from severe hepatic fibrosis in clinical subjects. This may be due to the fact that the severity of fibrosis is far more pronounced in experimental murine models than is found in schistosomiasis patients due to the fact that only one worm pair in a mouse represents a high level of infection if body size is taken into consideration. Of note, the down-regulation of serum levels of miR-200b-3p and miR-222 was also observed at 4 weeks p.i. in C57BL/6 mice, the time point when hepatic fibrosis is minimal, indicating other unknown factors may contribute to the serum dysregulation of these two miRNAs.

Detection of an individual miRNA provided only moderate diagnostic value for staging schistosomal hepatic fibrosis (AUC from 0.6270 to 0.6838); although similar to miR-150-5p, the best diagnostic performance was obtained with the combination of miR-150-5p, let-7a-5p and miR-146a-5p (AUC: 0.6997) ([Table 3](#t0015){ref-type="table"}). These values are comparable with the ELF test (AUC: 0.68) and HA serum levels (AUC: 0.69) for differentiating grade II-III fibrosis from grade 0-I fibrosis for the same human cohort used here \[[@bb0185]\]. And the ELF test has been previously considered superior to simple panels (such as Fibrosis-4 and aspartate aminotransferase to platelet ratio) in detecting advanced fibrosis \[[@bb0185]\]. The modest AUC values for predicting the severity of schistosomal hepatic fibrosis in this targeted human cohort may be attributable to a number of factors: 1) During schistosome infection, multiple tissues are affected in addition to the liver, such as the intestine, spleen, kidney and other ectopic sites \[[@bb0015]\], which likely affect the levels of the targeted miRNAs; 2) Co-parasitism with intestinal helminths and protozoa has been shown to be common in the targeted cohort \[[@bb0085],[@bb0195]\], a feature which may affect the host immune system and further impact the expression of the miRNAs considered here; 3) As the human study cohort was located in a medium-high prevalence schistosomiasis-endemic area, re-infection of some individuals with *S. japonicum* may also impact on miRNA expression levels in serum. 4) Due to living with rudimentary water sources, sanitation, and hygiene, the rates of acute respiratory infections, diarrheal diseases, and other communicable diseases in the targeted cohort are, likewise, high \[[@bb0195]\], another factor potentially affects the expression of investigated serum miRNAs. Nevertheless, increased levels of miR-150-5p, let-7a-5p, let-7d-5p and miR-146a-5p were measurable in the sera of C57BL/6 mice following the regression of liver fibrosis at 6 months post-treatment with PZQ, further indicating the potential utility of these miRNAs in staging schistosomal hepatic fibrosis.

Although the current work provides a key first step in identifying unique circulating host miRNAs associated with liver fibrosis caused by *S. japonicum* infection, only a limited number of miRNAs were tested in the study. In the future, it will be important to identify more potential miRNAs specific for schistosomiasis fibrosis based on serum miRNA profiling. Also, the relatively limited number of human samples tested may have impacted on our power to find statistically significant associations and increased diagnostic scores. A previous study showed that the use of vesicle-associated miRNAs produced a more sensitive representation of fibrosis grading \[[@bb0130]\], while another report did not \[[@bb0150]\]. It would thus be informative to determine whether serum vesicle-derived miRNAs improve on the ability in grading fibrosis in schistosomiasis.

In summary, by utilizing two mouse strains as schistosome infection models and then validation with a clinical cohort of schistosomiasis, we identified four circulating miRNAs that are associated with the staging of schistosomal hepatic fibrosis. The diagnostic performance of one of these miRNAs, miR-150-5p, for discriminating mild from severe fibrosis is comparable to the ELF test and serum level of HA. Circulating miRNAs may be a supplement for assessing hepatic fibrosis progression in human schistosomiasis.
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[^1]: Current address: Department of Pathology, JONELTA Foundation School of Medicine, University of Perpetual Help Rizal, Manila, Philippines.

[^2]: Correlations were calculated by Pearson\'s correlation coefficient (r).

[^3]: Abbreviations: AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; HP: Hydroxyproline; HF: Hepatic fibrosis; Gra: Granuloma; Nec: Necrosis; ns: no significant difference.

[^4]: Percentage in total liver section.

[^5]: EPG: Egg per gram feces.

[^6]: Serological testing involved detection of IgG antibodies against a combination of *S. japonicum* recombinant antigens (SjSAP4 and Sj23-LHD) \[[@bb0040]\].
